Cardiometabolic syndrome and chronic kidney disease

Current Diabetes Reports

Volumn 6, Issue 3, 2006, Pages 207-212

  Lastra, Guido ^b   Manrique, Camila ^b   McFarlane, Samy I ^b   Sowers, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; GROWTH FACTOR; INSULIN;

BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; OBESITY; OXIDATIVE STRESS; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; UNITED STATES;

ALBUMINURIA; CHRONIC DISEASE; ENDOPLASMIC RETICULUM; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; KIDNEY DISEASES; METABOLIC SYNDROME X; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 33745285785     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0036-5     Document Type: Review

References (56)

1. Manrique C, Lastra G, Whaley-Connell A, Sowers JR: Hypertension and the cardiometabolic syndrome. J Clin Hypertens 2005, 7:471-476.
2. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2005.
3. El-Atat Fadi, Stas SN, McFarlane SI, Sowers JR: The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004, 15:2816-2827.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative [no authors listed]. Am J Kidney Dis 2002, 39:S1-S246.
5. Coresh J, Astor BC, Greene T, et al.: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
6. Biesenback G, Hubmann R, Grafinder P, et al.: 5-year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched nondiabetic patients with end-stage renal disease from a single dialysis center from 1991 to 1997. Diabetes Care 2000, 23:1860-1862.
7. Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and Chronic Kidney Disease in U.S. Adults. Ann Intern Med 2004, 140:167-174.
8. Tanaka H, Shiohira Y, Uezu Y, et al.: Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006, 69:369-374.
9. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adult. J Am Soc Nephrol 2005, 16:2134-2140.
10. Fliser D, Pacini G, Engelleiter R, et al.: Insulin resistance and hyperinsulinemia are already present in patient with incipient renal disease. Kidney Int 1998, 53:1343-1347.
11. Chen J, Munter P, Hamm LL, et al.: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003, 14:469-477.
12. Hsu C, McCulloch CE, Iribarran C, et al.: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
13. Boes E, Fliser D, Ritz E, et al.: Apolipoprotein A-IV predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 2006, 17:528-536.
14. Hsu CC, Kao WHL, Coresh J, et al.: Apolipoprotein E and progression of chronic kidney disease. JAMA 2005, 293:2892-2899.
15. El-Atat F, Aneja A, McFarlane S, Sowers JR: Obesity and hypertension. Endocrinol Metab Clin North Am 2003, 32:823-854.
16. Cheng LS, Davis RC, Raffel LJ, et al.: Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive Hispanic families. Circulation 2001, 104:1255-1260.
17. Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004, 15:2792-2800.
18. Cusumamo AM, Bodkini NL, Hansen BC, et al.: Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 2002, 40:1075-1083.
19. Mangrum A, Bakris GL: Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications 1997, 11:352-357.
20. Abuisha B, Kumar S, Malik R, Boulton AJ: Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998, 39:93-99.
21. Steinke JM, Sinaiko AR, Kramer MS, et al.: The early natural history of nephropathy in type 1 diabetes. III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005, 54:2164-2171.
22. Bakris GL: Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep; 2004, 6:352-356
23. Cohen AJ, McCarthy DM, Stoff JS: Direct hemodynamic effect of insulin in the isolated perfused kidney. Am J Physiol 1989, 257:580-585.
24. Dengel DR, Goldberg AP, Mayuga RS, et al.: Insulin resistance, elevated glomerular filtration and renal injury. Hypertension 1996, 28:127-132.
25. Catalano C, Muscelli E, Quinones Galvan A, et al.: Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 1997, 46:868-875.
26. Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2001, 86:713-318.
27. Young BA, Johnson RJ, Alpers CE, et al.: Cellular events in the evolution of diabetic nephropathy. Kidney Int 1995, 47:935-944.
28. Aron DC, Rosenzweig JL, Abboud HE: Synthesis and binding of insulin-like growth factor 1 by human glomerular mesangial cells. J Clin Endocrinol Metab 1989, 68:585-591.
29. Conti FG, Stroker LJ, Lesniak MA, et al.: Studies on binding and mitogenic effect of insulin and insulin-like growth factor 1 in glomerular mesangial cells. Endocrinology 1988, 122:2788-2795.
30. Mooney A, Jobson T, Bacon R, et al.: Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol: 1997, 159:3949-3960.
31. Anderson PW, Zhang XY, Tian J, et al.: Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 1996, 50:745-753.
32. Wang S, Denichilo M, Brubaker C, Hirschberg R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 2001, 60:96-105.
33. Ferri C, Pittoni V, Piccoli A, et al.: Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 1995, 80:829-835.
34. Ferri C, Bellini C, Desideri G, et al.: Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 1996, 19:504-506.
35. Simonson MS, Herman WH: Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G protein-coupled receptors. J Biol Chem 1993, 268:9347-9357.
36. Juhan-Vague I, Alessi MC: PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997, 78:656-660.
37. Hirano T, Kashiwazaki K, Moritomo Y, et al.: Microalbuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res Clin Pract 1997, 36:11-18.
38. Rerolle JP, Hertig A, Nguyen G, et al.: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000, 58:1841-1850.
39. Robertson RP, Harmon J, Tran PO, et al.: Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
40. Ozcan U, Cao Q, Yilmaz E, et al.: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
41. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57:1803-1817.
42. Navar LG: Intrarenal renin-angiotensin system in hypertension. Kidney Int 2004, 65:1522-1532.
43. Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
44. Kobori H, Nishiyama A, Abe Y, Navar LG: Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003, 41:529-597.
45. Ruan X, Wagner C, Chatziantoniou C, et al.: Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet. J Clin Invest 1997, 99:1072-1081.
46. Wiecek A, Chudek J, Kokot F: Role of angiotensin II in the progression of diabetic nephropathy - therapeutic implications. Nephrol Dial Transplant 2003, 18:v16-v20.
47. Ruiz-Ortega M, Rupérez; M, Esteban V, et al.: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases Nephrol Dial Transplant 2006, 21:16-20.
48. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, et al.: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005, 111:2509-2517.
49. Ruiz-Ortega M, Lorenzo O, Ruperez; M, et al.: Systemic infusion of angiotensin II into normal rats activates nuclear factor kappa-B and AP-1 in the kidney. Role of AT1 and AT2 receptors. Am J Pathol 2001, 158:1743-1756.
50. Lorenzo E, Ruiz-Ortega M, Suzuki Y, et al.: Angiotensin III activates nuclear transcription factor-kappa B in cultured mesangial cells mainly via AT2 receptors: studies with AT1 receptor-knockout mice. J Am Soc Nephrol 2002, 13:1162-1171.
51. Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
52. Aldigier JC, Kanjanbuch T, Ma LJ, et al.: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16:3306-3314.
53. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063-1068.
54. Hostetter TH, Kren S, Ibrahim HN: Mineralocorticoid receptor blockade in the remnant kidney model [abstract]. J Am Soc Nephrol 1999, 10:75.
55. Nagai Y, Miyata K, Sun GP, et al.: Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-1045.
56. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.